Historique
Périodique
Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data - the ANRS-Coquelicot Study
Auteur(s) :
JAUFFRET-ROUSTIDE, M. ;
EMMANUELLI, J. ;
QUAGLIA, M. ;
BARIN, F. ;
ARDUIN, P. ;
LAPORTE, A ;
DESENCLOS, J. C.
Année
2006
Page(s) :
1603-1621
Langue(s) :
Français
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus géographique
FRANCE
Thésaurus mots-clés
VIH
;
POLITIQUE
;
EPIDEMIOLOGIE
;
ENQUETE
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
HEPATITE
;
ETUDE TRANSVERSALE
;
PREVALENCE
;
INFECTION
Note générale :
Substance Use and Misuse, 2006, 41, (10-12), 1603-1621
Résumé :
ENGLISH :
In France a harm-reduction policy was implemented in the late 1980s with the aim of reducing the prevalence of HIV and hepatitis C virus (HCV) infection among drug users. The ANRS-Coquelicot survey was designed to measure the prevalence of HIV and HCV infection among drug users and to examine determinants of at-risk behaviors. In 2002, information was collected from 166 drug users recruited in all types of services specializing in drug use intervention and harm reduction in Marseille, France. Self-reported HIV and HCV serostatus was compared with the results of serological tests done on capillary blood collected on filter paper. The self-reported and biologically documented prevalence rates of HIV infection were identical (22%). In contrast, the self-reported prevalence of HCV infection was 52%, whereas the biologically documented prevalence was 73%. Overall, 30% of HCV-infected drug users were unaware of their status. Forty-four percent of drug users under 30 years of age were HCV seropositive, suggesting that they had been infected early during drug use. The harm-reduction policy seems to have had a marked impact on HIV transmission among drug users but a much more limited impact on HCV transmission. The limitations and implications of the study are discussed. (Author' s abstract)
Affiliation :
National Institute for Public Health Surveillance, Saint-Maurice. Email : m.jauffret@invs.sante.fr
France. France.
France. France.
Cote :
A02975